Day: April 17, 2025

  Multitude Capital Oyj Publishes its Financial Statements 2024    Helsinki, 17 April 2025 – Multitude Capital Oyj (the Company) has today published its Financial Statements, Report of the Board of Directors and Corporate Governance Statement for the year 2024. The Company’s auditor, audit firm PricewaterhouseCoopers Oy has audited the Company’s Financial Statements and issued an Auditor’s Report. The documents have been published in English and are available on Multitude Group’s website under the subsidiary section Multitude Capital Oyj.    The Company is a wholly-owned subsidiary of Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized enterprises, and other FinTechs.    The Company has prepared the Financial Statements and the Report of the Board of...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly dosing for all approved indications would provide greater dosing flexibility for physicians and patients TARRYTOWN, N.Y., April 17, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA HD® (aflibercept) Injection 8 mg. The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every...

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application submission expected in the second quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, April 17, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare, inherited neurodegenerative disorder for which there are currently no disease-modifying therapies available. This designation is in addition to Regenerative Medicine Advanced Therapy (RMAT) designation,...

Notice to the Annual General Meeting of Virtune AB The shareholders of Virtune AB ( Publ ) corporate ID number 559175–2067, with registered office in Stockholm, are hereby summoned to the Annual General Meeting on Wednesday, May 21, 2025 at 4:00 PM. The Annual General Meeting will not take place digitally but will take place physically at the company’s premises at Kungsgatan 26, 111 35 in Stockholm. Registration etc.Shareholders who wish to participate in the Annual General Meeting must register with the company by email no later than Friday, May 16, 2025, no later than 5:00 p.m. Registration for participation in the Annual General Meeting must be made to email: hello@virtune.com. When registering, name, address, personal or corporate identity number, telephone number and shareholding must be stated and, where applicable, the name...

BEIJING, April 17, 2025 (GLOBE NEWSWIRE) — KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 17, 2025. The annual report can be accessed on the Company’s investor relations website at http://investors.ke.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company’s Investor Relations Department at ir@ke.com. About KE Holdings Inc. KE Holdings Inc. is a leading integrated online and offline platform...

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) — Amwell® (NYSE: AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company’s operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company’s website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access...

Not for release to US wire services or distribution in the United States Highlights:Robex Resources has lodged a prospectus with the Australian Securities and Investment Commission (ASIC) for an Initial Public Offer to raise A$120M (before costs) IPO is fully underwritten by joint lead managers, Euroz Hartleys Limited and Canaccord Genuity It proposes to issue 38,585,209 CHESS Depository Interests (CDIs) at A$3.11 each (~C$2.73) under the IPO Robex, a West African gold producer and developer listed on the TSX Venture Exchange (TSX-V) in Canada, expects to list on the Australian Securities Exchange (ASX) in early June 2025 Completion of the IPO will ensure development and construction of the Kiniero Gold Project, now fully funded through to first production, which is expected in late 2025QUEBEC CITY, April 17, 2025 (GLOBE NEWSWIRE)...

CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) (“CEMATRIX” or the “Company“), a specialty construction contractor that produces cellular concrete solutions on site and is a leading manufacturer and supplier of cellular concrete in North America announced today that it has won $9.7 million in new contract awards.   New Contract Award Details: Notable projects include:a significant contract for a tunnel grouting application; a change order increasing the contract value for lightweight fill on a light rail transit extension project.“Our focus is on providing value to our customers by consistently delivering a quality product, on time and on budget,” stated Randy Boomhour, President and CEO of CEMATRIX Corporation. “Every successful project strengthens...